Focused On-demand Library for Zona pellucida sperm-binding protein 2

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

PARTNER
Receptor.AI
 
UPACC
Q05996

UPID:
ZP2_HUMAN

ALTERNATIVE NAMES:
Zona pellucida glycoprotein 2; Zona pellucida protein A

ALTERNATIVE UPACC:
Q05996; B2R7J2; Q4VAN9; Q4VAP0; Q4VAP1

BACKGROUND:
Zona pellucida sperm-binding protein 2, alternatively named Zona pellucida glycoprotein 2 or Zona pellucida protein A, is integral to the fertilization process. As part of the zona pellucida, it ensures sperm binding, triggers the acrosome reaction, and blocks polyspermy. Its function as a secondary sperm receptor underscores its importance in successful fertilization.

THERAPEUTIC SIGNIFICANCE:
Associated with the infertility disorder Oocyte/zygote/embryo maturation arrest 6, due to abnormal sperm-binding, the study of Zona pellucida sperm-binding protein 2 holds promise for developing treatments for fertilization failures. Its pivotal role in fertilization highlights its potential in therapeutic applications.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 933 of 8789